- Home
- PASG vs HOWL Comparison
PASG vs HOWL Comparison
Compare PASG & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PASG | HOWL |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | United States |
| Employees | 27 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.8M | 17.9M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PASG | HOWL |
|---|---|---|
| Price | $4.61 | $0.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $14.00 | $5.00 |
| AVG Volume (30 Days) | 36.2K | ★ 807.9K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.40 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.29 | $0.27 |
| 52 Week High | $20.00 | $2.23 |
Technical Indicators
Market Signals| Indicator | PASG | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 44.39 | 51.04 |
| Support Level | $4.25 | $0.38 |
| Resistance Level | $5.04 | $0.43 |
| Average True Range (ATR) | 0.25 | 0.05 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 41.79 | 32.68 |
Price Performance
Historical ComparisonAbout PASG Passage Bio Inc.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.